CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model

Published:2017-03 Issue:2 Volume:484 Page:262-268
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Imayoshi Natsuki,Yoshioka Makoto,Chauhan Jay,Nakata Susumu,Toda Yuki,Fletcher Steven,Strovel Jeffrey W.,Takata Kazuyuki,Ashihara Eishi

Funder

Grant-in-Aids

MEXT-Supported Program

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference30 articles.

1. Novel agents in the treatment of multiple myeloma: a review about the future;Naymagon;J. Hematol. Oncol.,2016

2. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future;Bjorkstrand;Semin. Hematol.,2007

3. New drugs for myeloma;Richardson;Oncologist,2007

4. Targeting the canonical Wnt/beta-catenin pathway in hematological malignancies;Ashihara;Cancer Sci.,2015

5. AKT as a therapeutic target in multiple myeloma;Keane;Expert Opin. Ther. Targets,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor;Bioorganic & Medicinal Chemistry Letters;2023-04

2. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations;Genes & Diseases;2022-03

3. Successful Incorporation of Exosome-Capturing Antibody-siRNA Complexes into Multiple Myeloma Cells and Suppression of Targeted mRNA Transcripts;Cancers;2022-01-23

4. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia;Biochemical and Biophysical Research Communications;2022-01

5. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation;Biochemical and Biophysical Research Communications;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3